LEADER 03156nam  2200469z- 450 
001 9910346756503321
005 20210211
035   $a(CKB)4920000000094149
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/49485
035   $a(oapen)doab49485
035   $a(EXLCZ)994920000000094149
100   $a20202102d2018      |y         0
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aHIV-Induced Damage of B Cells and Production of HIV Neutralizing Antibodies
210   $cFrontiers Media SA$d2018
215   $a1 online resource (171 p.)
225 1 $aFrontiers Research Topics
311 08$a2-88945-461-4 
330   $aMultiple dysfunctions take place in the B cell compartment during HIV-1 infection, comprising depletion of resting memory B cells carrying serological memory to vaccines and previously met pathogens. In addition, population of B cells characterized by the expression of exhaustion markers are enlarged during HIV-1 infection. Antibodies with the capacity to neutralize a broad range of HIV-1 isolates can be detected only in a minority of infected patients, after a year or more from acute infection. An open question is whether the inability of producing neutralizing HIV-1 antibodies is somehow linked to the B cell immunopathology observed in patients. In this research topic we invited scientists to summarize the current state of knowledge on regulation and development of B cells and antibody responses during HIV-1 infection; fifteen contributions were received comprising both reviews and original articles. The articles are related to B cell dysfunctions identified in HIV-1 infected individuals, production of different types of antibodies (neutralizing versus non neutralizing, and of different isotypes) in vivo during HIV-1 infection and the biological factors which may impact on this process, clinical potential and applications of anti-HIV antibodies and how to achieve neutralizing antibody responses to HIV-1 epitopes upon vaccination. The topic has gathered articles on front-line research undertaken in the field of B cells and antibodies in HIV-1 infection. It is our hope that the collection of articles presented in this book may be useful for new and experienced scholars in the field and add a piece to the complex puzzle of knowledge needed for the development of an HIV-1 vaccine.
606   $aMedicine$2bicssc
610   $aauto-antibodies to CCR5
610   $aB cells
610   $aBAFF
610   $aclinical potential of HIV-1 antibodies
610   $aCXCL13
610   $aFcRL4
610   $aGene Expression
610   $aHIV-1 vaccine targets
610   $amaternal HIV antibodies
610   $amucosal IgA responses
610   $aneutralizing and non neutralizing HIV-1 antibodies
615  7$aMedicine
700   $aFrancesca Chiodi$4auth$01312840
702   $aGabriella Scarlatti$4auth
906   $aBOOK
912   $a9910346756503321
996   $aHIV-Induced Damage of B Cells and Production of HIV Neutralizing Antibodies$93031015
997   $aUNINA